The field of protein degradation has accelerated, and substantial interest is owed to its promise to therapeutically degrade proteins proving intractable to classical small molecule inhibition. As the field patiently waits for clinical trial readouts, some say we are entering the next era, beyond current targets and disease indications.
11-12 October 2022